Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07515625 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer (GC)
AFP Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Sintilimab
DRUG: Bevacizumab
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: S-1

Sponsor

Fudan University